The Advisory Committee on Immunization Practices, a panel that advises on U.S. vaccine policy, made a significant decision on Friday regarding the hepatitis B vaccine. In a contentious 8-3 vote, the committee recommended a delay in the administration of the hepatitis B vaccine to most babies, overturning a 30-year-old policy that has been instrumental in reducing cases of the virus.
The new recommendation suggests that parents discuss with their doctors whether to give the hepatitis B vaccine to their newborn at birth or wait until the baby is at least 2 months old. This recommendation applies to mothers who test negative for hepatitis B during pregnancy. Previously, the CDC recommended that all babies receive a dose of the hepatitis B vaccine within 24 hours of birth to protect them from the virus.
However, the policy remains unchanged for babies born to mothers who tested positive for hepatitis B during pregnancy or whose status is unknown. They should still receive a dose of the vaccine at birth along with hepatitis B immune globulin.
Another recommendation, passed by a vote of 6 to 4 with 1 abstention, suggests that parents who choose to vaccinate their babies against hepatitis B should consider testing the child after the first dose to determine if additional doses are necessary for long-term protection.
The decision to delay the administration of the hepatitis B vaccine has sparked debate among medical experts, vaccine manufacturers, and the anti-vaccine movement. While some support the change, others argue that delaying the vaccine could lead to an increase in cases of chronic hepatitis B infection and related complications.
The ACIP meeting where the decision was made was described as historic, with experts expressing concerns about the lack of scientific evidence supporting the new recommendations. Critics of the decision fear that it may undermine the progress made in reducing hepatitis B infections in infants over the past three decades.
The new recommendations must be endorsed by the acting director of the CDC or the health secretary before they can be implemented. The decision marks a significant shift in U.S. vaccine policy and has raised concerns about the influence of anti-vaccine groups on public health decisions.
